

Estimate changes

TP change

Rating change

Bloomberg	DABUR IN
Equity Shares (m)	1774
M.Cap.(INRb)/(USDb)	901.1 / 10.2
52-Week Range (INR)	577 / 420
1, 6, 12 Rel. Per (%)	-3/-2/-12
12M Avg Val (INR M)	1362

Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Sales	133.1	144.9	156.4
Sales Gr. (%)	5.9	8.9	7.9
EBITDA	25.0	27.7	30.3
EBITDA mrg. (%)	18.8	19.1	19.4
Adj. PAT	19.2	21.6	23.7
Adj. EPS (INR)	10.8	12.2	13.4
EPS Gr. (%)	6.7	12.4	9.7
BV/Sh.(INR)	65.4	67.2	68.7

Ratios

RoE (%)	17.2	18.4	19.7
RoCE (%)	15.9	16.9	18.1
Payout (%)	87.6	90.2	93.4

Valuation

P/E (x)	46.1	41.0	37.4
P/BV (x)	7.6	7.4	7.3
EV/EBITDA (x)	32.0	28.6	25.9
Div. Yield (%)	1.9	2.2	2.5

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	66.2	66.2	66.3
DII	17.4	16.2	13.7
FII	10.9	11.8	15.0
Others	5.5	5.7	5.0

FII Includes depository receipts

CMP: INR508 TP: INR525 (+3%) Downgrade to Neutral

Execution weakness persists; weak commentary for 2HFY26

- Dabur's 2QFY26 performance was largely in line with our estimates. Consolidated revenue grew ~5% YoY. India business revenue grew 6% YoY and domestic volume growth stood at 2%. The GST transition and prolonged monsoon weighed on performance during the quarter. The GST transition and trade pipeline adjustments impacted revenue growth by ~3-4%.
- Home & personal care revenue rose 9%, backed by strong performance in oral care, home care, and skin care. The healthcare portfolio remained muted, posting 1% growth. F&B clocked 2% YoY growth, while the food portfolio reported double-digit growth. Beverages were impacted by heavy rainfall. The international business grew 5.5% YoY in cc terms and 7.7% in INR terms.
- GM expanded 10bp YoY to 49.4% (est. 48.8%), and EBITDA margin rose 20bp YoY to 18.4% (est. 18.3%). EBITDA grew 6% despite a favorable base (-16% in 2QFY25). Management highlighted that there was ~8% inflation during the quarter, which was mitigated by price hikes of ~4% and cost-saving initiatives.
- The company has been witnessing muted sales growth over the past two years, primarily due to weak rural demand and unfavorable seasonal conditions. The performance has become more sluggish since 2QFY25 post channel destocking. Given the GST 2.0 benefits, shift of channel filling in 2HFY26, and expectations of better growth of its winter portfolio (favorable base too), we were expecting a much better 2HFY26 print. However, management commentary remained weak, with expectations of only mid- to high-single-digit revenue growth in 2HFY26, supported by mid-single-digit volume growth. Dabur's consistent weak execution is limiting our confidence in its growth recovery despite macros turning positive. Given the slower-than-expected turnaround, we lower our valuation multiple from 45x to 40x and **downgrade the stock from BUY to Neutral, with a revised TP of INR 525 (40x Sep'27E EPS)**.

In-line performance; 2% volume growth

- **Mid-single digit revenue growth:** Dabur's 2QFY26 consolidated sales grew by 5.4% (inline) to INR31.9b (est. INR32.1b). Indian business revenue grew by 5.7% YoY. Indian business volume growth stood at 2%. (est. 6%).
- **HPC business grew 9% YoY:** Oral Care grew in double digits YoY. The toothpaste business grew 14%, backed by Dabur Red and Meswak. Skin care grew in high single digits. Home care and hair care grew in mid-single digits.

Naveen Trivedi – Research Analyst (Naveen.Trivedi@motilaloswal.com)

Research Analyst: Amey Tiwari (Amey.Tiwari@motilaloswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Healthcare portfolio up 1% YoY:** Health supplements grew in mid-single digits, backed by Dabur honey's double-digit growth (high twenties). Digestives grew in low single digits. OTC & Ethicals decline in mid-single digit due to the discontinuation of the Diaper Baby Super pants and temporary disruption in trade due to the GST transition.
- **Foods and beverages grew 2%:** Foods portfolio grew in double digits. The 100% Fruit Juice portfolio under the Real Active brand grew by over 45%, while Real Juices' portfolio was impacted during the quarter on account of heavy rainfalls, floods, and landslides.
- International growth was at 5.5% in CC terms and 7.7% in INR terms.
- **Flat margins:** Gross margin expanded marginally 10bp YoY to 49.4% (est. 48.8%). Employee expenses rose 3%, ad spends increased 4%, and other expenses rose 8% YoY. EBITDA margin expanded 20bp YoY to 18.4% (est. 18.3%).
- In 1H FY26, net sales, EBITDA, and APAT grew 3%, 4% and 4%, respectively.

Highlights from the management commentary

- For the last six consecutive quarters, rural markets have outperformed urban markets.
- GST rate reductions across nearly 66% of the Indian portfolio are likely to boost consumption in the coming quarters by improving affordability and channel confidence. Currently, 86% of the company's portfolio falls under the 5% tax bracket.
- Key inflation drivers during the quarter included higher costs of packaging materials (PET, laminates) and certain agri-linked inputs like sugar and honey, leading to a weighted average inflation of ~8%.
- In international markets, key markets such as the UK, Turkey, Bangladesh, Nigeria, and Dubai witnessed healthy performance, while Nepal saw a temporary slowdown due to political disruptions.

Valuation and view

- We cut our EPS estimates by 2% for FY26 and 3% each for FY27 and FY28.
- The company has been witnessing muted sales growth over the past two years. After delivering only 1.3% growth in FY25, revenue growth improved modestly to 3% in 1H FY26, and management is guiding for mid- to high-single-digit growth in 2H FY26, supported by mid-single-digit volume growth.
- We remain positive on consumption recovery, supported by improving macros and GST reforms; however, Dabur's weak execution is limiting our confidence in the company's near-term revival.
- Given the slower-than-expected turnaround, we lower our valuation multiple from 45x to 40x and **downgrade the stock from BUY to Neutral, with a revised TP of INR 525 (40x Sep'27E EPS).**

Quarterly Performance (Consolidated)

(INR m)

Y/E March	FY25				FY26				FY25	FY26E	FY26E	Var. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	
Domestic FMCG vol. growth (%)	5.2	-7.0	1.2	-5.0	-1.0	2.0	10.5	8.0	-1.4	4.9	6.0	
Net sales	33,491	30,286	33,553	28,301	34,046	31,913	36,342	30,788	1,25,631	1,33,089	32,067	-0.5%
YoY change (%)	7.0	-5.5	3.1	0.6	1.7	5.4	8.3	8.8	1.3	5.9	5.9	
Gross profit	16,005	14,943	16,124	13,211	16,013	15,778	17,735	14,623	60,282	64,149	15,649	0.8%
Margin (%)	47.8	49.3	48.1	46.7	47.0	49.4	48.8	47.5	48.0	48.2	48.8	
EBITDA	6,550	5,526	6,819	4,269	6,678	5,881	7,559	4,903	23,163	25,021	5,868	0.2%
Margins (%)	19.6	18.2	20.3	15.1	19.6	18.4	20.8	15.9	18.4	18.8	18.3	
YoY growth (%)	8.3	-16.4	2.1	-8.6	2.0	6.4	10.9	14.9	-3.5	8.0	6.2	
Depreciation	1,091	1,110	1,086	1,169	1,141	1,154	1,194	1,172	4,456	4,661	1,130	
Interest	327	474	442	393	346	397	375	357	1,635	1,475	375	
Other income	1,294	1,515	1,280	1,412	1,440	1,401	1,400	1,462	5,501	5,703	1,475	
PBT	6,427	5,457	6,571	4,119	6,630	5,731	7,390	4,836	22,573	24,588	5,839	-1.8%
Tax	1,481	1,284	1,418	992	1,543	1,282	1,810	1,387	5,175	6,023	1,430	
Rate (%)	23.0	23.5	21.6	24.1	23.3	22.4	24.5	28.7	22.9	24.5	24.5	
Adjusted PAT	5,084	4,333	5,306	3,284	5,222	4,608	5,742	3,650	18,006	19,222	4,570	0.8%
YoY change (%)	7.7	-17.2	1.6	-8.2	2.7	6.4	8.2	11.2	-4.0	6.7	5.5	

E: MOFSL Estimates

Exhibit 1: Category-wise performance

Business Segment	Category	1QFY25	2QFY25*	3QFY25	4QFY25	1QFY26	2QFY26
Healthcare	Health Supplements	7.8	-11.2	-3.4	0.5	3	5
	Digestives	10.7	-7.7	3.9	-2.1	7.7	2
	OTC & Ethical	3.7	-14	0.4	-8.4	2	-5
Home and Personal Care	Oral Care	11.4	-8.7	9.1	-5.2	5	14
	Hair care	3.3	-10.2	2.7	-4.6	2	5
	Home care	8	-4.9	5	0.9	10.1	5
	Skin & Salon	6.1	-14	5.6	8	9.2	8
Foods	Beverages	2.8	-21.6	-10.3	-9.2	-20	-12
	Foods	21.3	10.6	30	14.2	12	14

Sources: Company reports, MOFSL



Highlights from the management commentary

Demand and Environment

- Overall demand environment remained mixed, with a softer start to the quarter due to heavy rainfall, floods, and GST-related trade disruptions.
- Rural markets continued to outperform urban, supported by improved farm cash flows, normal monsoon in core states, and deeper distribution reach through Project SETU and last-mile coverage.
- Rural growth outpaced urban markets, driven by higher consumption of mass and mid-tier products and effective localized marketing initiatives.
- Urban markets witnessed steady demand in premium and health-oriented categories but were impacted by short-term disruptions post-GST announcement.
- Management indicated recovery in consumption trends in October with normalization of trade and gradual channel restocking.

GST Impact

- GST rate reductions across nearly 66% of the Indian portfolio are likely to boost consumption in the coming quarters by improving affordability and channel

confidence. Currently, 86% of the company's portfolio comes under the 5% tax bracket.

- The company has passed on benefits of GST cuts to consumers through price reductions in key categories such as Oral care, Hair care, Juices, Health Supplements, and Home Care.
- Temporary trade disruptions post the GST rate announcement affected secondary sales and supply chain flow during the quarter.
- Management expects GST rate cuts, especially the reduction from 12% to 5% in juices, to aid demand recovery in 2HFY25.
- However, the transition created short-term trade disruptions and inventory re-pricing effects that temporarily depressed sales in September and carried into early October.
- **Management estimates the one-off GST pipeline impact at ~INR1b (around 3-4% of sales) in 2QFY26.**
- The company took a grammage increase in 27% of its LUPs portfolio.

Inverted duty structure

- Dabur highlighted the issue of an inverted duty structure — where weighted average input tax (~8–8.5%) exceeds output tax (~6.5–7%) — creating a structural cost disadvantage of ~125–150 bps.
- The company is implementing seven identified cost and supply chain measures to partly offset the impact while engaging with authorities for long-term resolution.
- If not addressed systemically, management may consider selective price adjustments or portfolio rationalization to offset the gap.

Cost and Margin

- Dabur delivered stable to improving operating margins during the quarter despite persistent input cost inflation and temporary trade disruptions.
- Gross margin expanded by ~20 bps YoY, supported by a favorable mix shift towards premium and healthcare portfolios and effective cost optimization measures.
- Key inflation drivers during the quarter included higher costs of packaging materials (PET, laminates) and certain agri-linked inputs like sugar and honey, leading to a weighted average inflation of ~8%.
- To mitigate these pressures, the company implemented selective price hikes of 3–4% across key categories, including oral care, hair oils, and home care.
- Management indicated that premiumization, scale leverage, and operational efficiencies (in manufacturing and logistics) provided additional cushion to margins.
- The impact of input cost inflation was largely offset by these calibrated pricing actions and internal productivity initiatives.

International business

- International business grew 7.7% in INR terms and 5.5% in constant currency.
- Key markets such as the UK, Turkey, Bangladesh, Nigeria, and Dubai witnessed healthy performance, while Nepal saw a temporary slowdown due to political disruptions.

- Demand in GCC markets remained stable, and Africa continued to post healthy growth in the health supplements and home care segments.
- Management expects a pickup in international growth in 2HFY25 with increased brand support and new product introductions.

Winter Portfolio

- Winter products contribute significantly to Dabur's seasonal portfolio, led by Chyawanprash, Honitus, and Gulabari.
- The company is optimistic about strong winter demand, aided by normalizing trade post-GST and early festive loading in October.
- Management expects a higher offtake in immunity and skincare categories if the winter season is of normal to higher intensity.

Distribution

- Dabur continues to strengthen its rural distribution reach, with rural stockists and sub-stockist coverage expanding under Project SETU.
- The company now reaches over 1.4m retail outlets, with a focus on increasing direct coverage in semi-urban and rural areas.
- Rural secondary sales and off-take trends remain stronger than urban, aided by localized marketing campaigns and improved supply chain agility.
- Urban distribution efforts are focused on modern trade and e-commerce platforms, where premium SKUs are gaining traction.
- Distributor inventory levels normalized to ~22 days, indicating efficient stock management post-GST transition.

Channels

- E-commerce and modern trade channels continued to deliver robust double-digit growth.
- The contribution of digital channels increased, supported by strong sales in health supplements, personal care, and home care segments.
- General trade witnessed a temporary slowdown due to GST transition but is expected to recover strongly in 2HFY25. GT grew 7% in rural markets and 3% in urban markets.

New Launches

- Several new products were launched across segments:
 - Oral Care: New SKUs under Dabur Red and Meswak to enhance regional relevance.
 - Health Supplements: Honey variants with added health benefits.
 - Home Care: Odonil Natural and new aerosol formats.
 - Food & Beverages: Coconut water variants and new Activ Juices.
- Continuous focus on expanding the product portfolio and launching premium extensions to drive value growth.

M&A Plans and Dabur Ventures

- Dabur Ventures, a INR5b fund, has been established to invest in digital-first and high-growth consumer brands in adjacencies like health, wellness, and personal care.

- The Ventures division will pursue strategic minority or majority stakes in emerging D2C brands with the potential to scale.
- Management remains open to bolt-on acquisitions in both domestic and international markets that complement the core portfolio.

Guidance

- **Management guided for mid-to-high single-digit revenue growth and mid-single-digit volume growth for 2HFY25.**
- Margins are expected to expand sequentially with normalization of input costs and higher operating leverage.
- The company expects rural demand momentum to sustain and urban consumption to recover in H2 as trade stabilizes.

Segmental performance

HPC

The HPC portfolio performed well with 9% YoY growth.

Oral Care

- The toothpaste portfolio recorded robust ~14% year-on-year growth, continuing to outpace the overall category and gain market share.
- Both Dabur Red Toothpaste and Meswak maintained their strong growth trajectory, supported by effective marketing and increasing consumer preference for natural ingredient-based products.
- Non-herbal portfolio grew 5x of the herbal portfolio.

Skin Care

- The 'Gulabari' franchise delivered high single-digit growth, led by healthy performance of the flagship Gulabari Rose Water and the Face Freshener range.
- Fem and Oxy brands also performed well during the quarter, benefiting from sustained consumer demand and improved visibility across channels.

Home Care

- Odonil sustained its double-digit growth trajectory, driven by strong momentum in gel and aerosol formats, resulting in continued market share gains in the air freshener category.
- Sanifresh exhibited healthy performance with high single-digit growth, supported by improved penetration and effective brand activations.

Hair Care

- The shampoo category registered high single-digit growth along with market share gains, reflecting recovery in discretionary consumption and successful brand campaigns.
- The hair oils portfolio grew ahead of the overall category and continued to gain market share, aided by strong traction in value-added and Ayurvedic sub-segments.

Healthcare

The overall healthcare portfolio grew 1% YoY.

Health Supplements

- Dabur Honey delivered strong double-digit growth in the high twenties, driven by increased consumer focus on health and wellness and enhanced visibility across modern trade and e-commerce channels.
- Dabur Chyawanprash maintained its leadership position in the category, gaining 234 bps market share, supported by focused media initiatives and consistent brand communication emphasizing immunity benefits.

Digestives

- The Hajmola franchise registered double-digit growth and further strengthened its leadership position, gaining market share in the digestives category on the back of steady consumption trends and effective promotional activities.
- Pudín Hara Fizz continued to receive a positive consumer response, aided by focused advertising campaigns and expanded distribution reach.

OTC & Ethicals


- Honitus recorded strong double-digit growth, driven by seasonal demand and continued consumer trust in the brand's efficacy.
- Health Juices sustained their double-digit growth momentum, supported by rising consumer preference for natural and immunity-boosting beverages.
- The overall segment performance was partially impacted by the discontinuation of Diaper Baby Super Pants and temporary trade disruptions arising from the GST transition.

Food & beverages

- The foods and beverages segment saw 2% YoY growth in 2QFY26.
- The foods portfolio delivered double-digit growth during the quarter, led by strong performance in coconut milk, edible oils, and fats.
- The Activ range, which includes juices and coconut water, maintained its robust double-digit growth momentum, supported by higher penetration and increasing preference for healthier beverage options.
- The Real Juices portfolio, however, was impacted by heavy rainfall, floods, and landslides in key markets, which disrupted supply chains and affected on-ground consumption.
- The recent GST rate reduction from 12% to 5% on juices is expected to boost affordability and improve consumption trends in the coming quarters.
- Despite temporary headwinds in 2Q, the company outperformed the overall category, gaining 115 bp market share in the nectars category and a significant 1074 bp in the 100% juices segment, reaffirming its strong brand equity and market leadership.

Key exhibits

Exhibit 2: Domestic FMCG business volumes rose 2% YoY in 2QFY26



Sources: Company reports, MOFSL

Exhibit 3: Consolidated reported net sales rose 5.4% YoY to INR31.9b




Exhibit 4: Con. GP margin expanded 10bp YoY to 49.4%




Exhibit 5: EBITDA margin expanded 20bp YoY to 18.4%




Exhibit 6: Ad spends declined 20bp YoY to 7.3% and staff cost down 30bp YoY to 10.9%, while other expenses rose 30bp YoY to 12.8%





Exhibit 7: Consolidated adjusted PAT rose ~6% YoY to INR4.6b



Sources: Company reports, MOFSL

Valuation and view


- We cut our EPS estimates by 2% for FY26 and 3% each for FY27 and FY28.
- The company has been witnessing muted sales growth over the past two years. After delivering only 1.3% growth in FY25, revenue growth improved modestly to 3% in 1HFY26, and management is guiding for mid- to high-single-digit growth in 2HFY26, supported by mid-single-digit volume growth.
- We remain positive on consumption recovery supported by improving macros and GST reforms; however, Dabur's weak execution is limiting our confidence in the company's near-term revival.
- Given the slower-than-expected turnaround, we lower our valuation multiple from 45x to 40x and **downgrade the stock from BUY to Neutral, with a revised TP of INR 525 (40x Sep'27E EPS).**

Exhibit 8: We cut our EPS estimates by 2% for FY26 and 3% each for FY27 and FY28

	New			Old			% Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Net Sales	133.1	144.9	156.4	134.9	148.3	160.5	-1.3	-2.3	-2.5
EBITDA	25.0	27.7	30.3	25.5	28.8	31.5	-1.9	-3.8	-3.5
Adjusted PAT	19.2	21.6	23.7	19.7	22.4	24.5	-2.5	-3.4	-3.2


Source: MOFSL

Exhibit 9: DABUR's P/E (x)



Sources: Bloomberg, MOFSL

Exhibit 10: Consumer sector's P/E (x)



Sources: Bloomberg, MOFSL

Financials and valuations

Consol. Income Statement

(InR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Net Sales	85,150	86,846	95,683	1,08,960	1,15,379	1,24,040	1,25,631	1,33,089	1,44,927	1,56,428
Change (%)	10.3	2.0	10.2	13.9	5.9	7.5	1.3	5.9	8.9	7.9
Gross Profit	42,240	43,434	47,944	52,563	52,692	59,571	60,282	64,149	70,290	76,337
Margin (%)	49.6	50.0	50.1	48.2	45.7	48.0	48.0	48.2	48.5	48.8
Other Expenditure	24,845	25,510	27,700	29,952	30,971	35,568	37,119	39,128	42,609	45,990
EBITDA	17,395	17,924	20,243	22,611	21,721	24,002	23,163	25,021	27,681	30,347
Change (%)	7.5	3.0	12.9	11.7	-3.9	10.5	-3.5	8.0	10.6	9.6
Margin (%)	20.4	20.6	21.2	20.8	18.8	19.4	18.4	18.8	19.1	19.4
Depreciation	1,769	2,205	2,401	2,529	3,110	3,992	4,456	4,661	4,673	4,885
Int. and Fin. Charges	596	495	308	386	782	1,242	1,635	1,475	1,200	1,200
Other Income - Recurring	2,962	3,053	3,253	3,932	4,454	4,824	5,501	5,703	6,082	6,365
Profit before Taxes	17,992	18,277	20,787	23,628	22,283	23,593	22,573	24,588	27,890	30,627
Change (%)	5.4	1.6	13.7	13.7	-5.7	5.9	-4.3	8.9	13.4	9.8
Margin (%)	21.1	21.0	21.7	21.7	19.3	19.0	18.0	18.5	19.2	19.6
Tax	4,070	4,654	3,630	4,422	4,816	5,395	4,991	5,954	6,901	7,471
Deferred Tax	-1,284	-1,857	-20	842	357	79	184	69	70	184
Tax Rate (%)	15.5	15.3	17.4	22.3	23.2	23.2	22.9	24.5	25.0	25.0
Profit after Taxes	15,206	15,480	17,176	18,364	17,110	18,118	17,399	18,565	20,919	22,971
Change (%)	10.8	1.8	11.0	6.9	-6.8	5.9	-4.0	6.7	12.7	9.8
Margin (%)	17.9	17.8	18.0	16.9	14.8	14.6	13.8	13.9	14.4	14.7
Minority Interest	30	25	17	31	-58	-314	-272	-330	-370	-416
Adjusted PAT	15,176	15,454	17,160	18,333	17,168	18,757	18,006	19,222	21,614	23,712
Exceptional Items	-753	-1,000	0	-850	16	-5	0	0	0	0
Reported PAT	14,423	14,454	17,160	17,483	17,184	18,427	17,676	18,892	21,284	23,382

Balance Sheet

(InR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Share Capital	1,766	1,767	1,767	1,768	1,772	1,772	1,772	1,772	1,772	1,772
Reserves	54,551	64,290	74,868	82,045	87,961	96,891	1,06,235	1,14,162	1,17,353	1,19,938
Net Worth	56,317	66,057	76,635	83,813	89,733	98,663	1,08,007	1,15,935	1,19,125	1,21,710
Minority Interest	314	365	367	406	4,682	4,368	4,096	4,426	4,796	5,212
Loans	5,288	4,718	4,847	10,072	11,434	11,581	7,301	7,101	6,901	6,701
Capital Employed	61,919	71,140	81,849	94,291	1,05,848	1,14,612	1,19,404	1,27,462	1,30,822	1,33,623
Gross Block	28,028	32,935	35,238	39,265	53,541	59,488	65,673	61,039	60,689	63,489
Less: Accum. Depn.	-11,698	-13,768	-16,169	-18,698	-21,807	-25,799	-30,255	-34,917	-39,590	-44,475
Net Fixed Assets	16,330	19,167	19,069	20,568	31,734	33,689	35,417	26,122	21,099	19,013
Capital WIP	638	1,466	1,473	1,675	1,751	2,091	1,690	1,690	1,690	1,690
Goodwill	3,361	3,360	3,360	2,512	4,053	4,051	4,051	3,551	3,051	2,551
Investments	33,588	28,003	41,484	62,102	62,574	69,254	75,114	77,614	80,114	82,614
Curr. Assets, L&A	30,451	41,325	42,199	35,983	37,854	42,079	46,026	56,237	65,751	71,693
Inventory	13,005	13,796	17,343	19,114	20,242	19,470	23,001	21,928	23,626	25,232
Account Receivables	8,336	8,139	5,616	6,462	8,488	8,987	8,885	9,412	10,250	11,063
Cash and Bank Balance	3,282	8,114	12,710	5,387	4,703	6,664	5,780	15,872	22,132	24,876
Others	5,828	11,277	6,531	5,021	4,422	6,958	8,360	9,024	9,744	10,522
Curr. Liab. and Prov.	22,216	22,226	26,484	27,732	31,229	35,525	41,476	36,334	39,464	42,521
Current Liabilities	19,812	19,475	23,126	23,884	28,446	32,343	38,157	32,812	35,730	38,566
Provisions	2,404	2,751	3,357	3,847	2,784	3,182	3,320	3,523	3,734	3,955
Net Current Assets	8,235	19,099	15,716	8,251	6,625	6,554	4,550	19,903	26,287	29,173
Deferred Tax Liability	-231	46	747	-816	-889	-1,027	-1,417	-1,417	-1,417	-1,417
Application of Funds	61,919	71,140	81,849	94,291	1,05,848	1,14,612	1,19,404	1,27,462	1,30,822	1,33,623

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)										
EPS	8.6	8.7	9.7	10.4	9.7	10.6	10.2	10.8	12.2	13.4
Cash EPS	9.2	9.4	11.1	11.3	11.5	12.7	12.5	13.3	14.6	15.9
BV/Share	31.9	37.4	43.4	47.4	50.6	55.7	60.9	65.4	67.2	68.7
DPS	4.0	4.5	4.8	4.8	5.2	5.5	8.0	9.5	11.0	12.5
Payout %	46.6	51.5	48.9	45.8	53.7	52.0	78.7	87.6	90.2	93.4
Valuation (x)										
P/E	58.2	57.2	51.5	48.2	51.6	47.2	49.2	46.1	41.0	37.4
Cash P/E	54.5	53.0	45.2	44.2	43.7	39.5	40.0	37.6	34.1	31.3
EV/Sales	10.0	9.8	8.7	7.6	7.2	6.6	6.5	6.0	5.5	5.0
EV/EBITDA	49.0	47.5	41.2	36.6	38.2	34.2	35.1	32.0	28.6	25.9
P/BV	15.7	13.4	11.5	10.5	9.9	9.0	8.2	7.6	7.4	7.3
Dividend Yield (%)	0.8	0.9	1.0	1.0	1.0	1.1	1.6	1.9	2.2	2.5
Return Ratios (%)										
RoE	26.8	25.3	24.1	22.9	19.8	19.9	17.4	17.2	18.4	19.7
RoCE	24.4	23.9	22.8	21.2	17.7	17.3	15.9	15.9	16.9	18.1
RoIC	53.2	45.9	49.4	60.8	46.1	41.9	39.3	44.5	58.3	74.4
Working Capital Ratios										
Debtor (Days)	36	34	21	22	27	26	26	26	26	26
Asset Turnover (x)	1.4	1.2	1.2	1.2	1.1	1.1	1.1	1.0	1.1	1.2
Leverage Ratio										
Debt/Equity (x)	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1

Cash Flow Statement

(InR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(loss) before Tax	17,249	17,276	20,787	22,778	22,187	23,587	22,579	24,588	27,890	30,627
Int./Div. Received	1,765	2,553	2	39	-1,038	-2,201	-566	330	370	416
Depreciation & Amort.	1,769	2,205	2,401	2,529	3,110	3,992	4,456	4,661	4,673	4,885
Interest Paid	-2,002	-2,001	308	386	-2,829	-2,689	-2,447	1,475	1,200	1,200
Direct Taxes Paid	-3,507	-3,089	-3,611	-5,264	-4,945	-4,939	-4,045	-6,023	-6,971	-7,655
(Incr)/Decr in WC	-181	-580	7,979	141	-1,601	2,385	-110	-5,261	-124	-141
CF from Oper.	15,092	16,364	27,867	20,609	14,884	20,135	19,868	19,770	27,038	29,331
(Incr)/Decr in FA	-2,344	-4,175	-2,311	-3,381	-4,857	-5,609	-5,695	5,134	850	-2,300
Free Cash Flow	12,748	12,190	25,556	17,228	10,027	14,526	14,172	24,904	27,888	27,031
(Pur)/Sale of Inv.	-53,928	-84,788	-13,481	-20,618	-4,950	-7,978	-61,884	-2,500	-2,500	-2,500
Others	60,600	86,031	-878	1,515	4,591	7,025	60,882	-3	-5	-5
CF from Invest.	4,329	-2,931	-16,670	-22,484	-5,216	-6,562	-6,698	2,631	-1,655	-4,805
Issue of Shares	5	1	-501	-1,006	4	0	0	0	0	0
(Incr)/Decr in Debt	-2,720	-1,751	129	5,226	488	-472	-2,168	-200	-200	-200
Dividend Paid	-15,970	-6,178	-5,921	-9,281	-9,213	-9,658	-9,748	-10,634	-17,723	-20,381
Others	-515	-673	-308	-386	-1,631	-1,483	-2,138	-1,475	-1,200	-1,200
CF from Fin. Act.	-19,200	-8,601	-6,602	-5,448	-10,352	-11,612	-14,053	-12,309	-19,123	-21,781
Incr/Decr of Cash	221	4,832	4,596	-7,323	-684	1,961	-883	10,092	6,260	2,744
Add: Opening Bal.	3,061	3,282	8,114	12,710	5,387	4,703	6,664	5,780	15,872	22,132
Closing Balance	3,282	8,114	12,710	5,387	4,703	6,664	5,780	15,872	22,132	24,876

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL), National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.